Effect of Pelargonium graveolens on Glucose Metabolism in Streptozotocin-Induced Diabetic Rats
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
AIMS: The study aimed to assess the antihyperglycemic activity of Pelargonium graveolens.
BACKGROUND: Pelargonium graveolens (P. graveolens) (Geraniaceae) is a medicinal plant frequently used in traditional medicine in Morocco and Algeria as remedy against a multitude of illnesses. Interestingly, it is used in the Moroccan pharmacopeia for managing diabetes.
OBJECTIVE: The current study was carried out in order to assess the antihyperglycemic activity of P. graveolens in normal and streptozotocin(STZ)-induced diabetic rats, as well as to evaluate the acute toxicity of the leaves aqueous extract of Pelargonium graveolens (PGLAE).
METHODS: The therapeutic effect of PGLAE at a dose of 40 mg/kg on blood glucose levels was investigated in normal and STZ-induced diabetic rats after a single oral (6h) and a repeated (15 days) oral administration. The acute toxicity of the PGLAE was examined in accordance the OECD test guideline. Post-treatment, body weight, signs of toxicity, and/or mortality were observed for 14 days. Further assays such as the oral glucose tolerance test, histopathological examination and antioxidant activity was also performed according to standard protocols.
RESULTS: Findings exhibited that both single and repeated oral doses of PGLAE (40 mg/kg) produced significant reduction of blood glucose levels in normal and diabetic rats. All treated animals survived and no apparent adverse effects were observed during the duration of the acute toxicity study. Importantly, oral LD50 of PGLAE was greater than 2000 mg/kg BW. Furthermore, a remarkable influence on glucose tolerance was also noticed after PGLAE treatment. Moreover, PGLAE was able to improve histopathological structure of liver and possesses a potential antioxidant effect in vitro.
CONCLUSION: In conclusion, this study reports the antidiabetic effect of PGLAE in rats supporting then its traditional use for the management of diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological disorders drug targets - (2022) vom: 16. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fadwa, El-Ouady [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antihyperglycemic |
|---|
| Anmerkungen: |
Date Revised 20.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1871529X22666220216102243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337023840 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337023840 | ||
| 003 | DE-627 | ||
| 005 | 20240220232031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871529X22666220216102243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM337023840 | ||
| 035 | |a (NLM)35170422 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fadwa, El-Ouady |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Pelargonium graveolens on Glucose Metabolism in Streptozotocin-Induced Diabetic Rats |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a AIMS: The study aimed to assess the antihyperglycemic activity of Pelargonium graveolens | ||
| 520 | |a BACKGROUND: Pelargonium graveolens (P. graveolens) (Geraniaceae) is a medicinal plant frequently used in traditional medicine in Morocco and Algeria as remedy against a multitude of illnesses. Interestingly, it is used in the Moroccan pharmacopeia for managing diabetes | ||
| 520 | |a OBJECTIVE: The current study was carried out in order to assess the antihyperglycemic activity of P. graveolens in normal and streptozotocin(STZ)-induced diabetic rats, as well as to evaluate the acute toxicity of the leaves aqueous extract of Pelargonium graveolens (PGLAE) | ||
| 520 | |a METHODS: The therapeutic effect of PGLAE at a dose of 40 mg/kg on blood glucose levels was investigated in normal and STZ-induced diabetic rats after a single oral (6h) and a repeated (15 days) oral administration. The acute toxicity of the PGLAE was examined in accordance the OECD test guideline. Post-treatment, body weight, signs of toxicity, and/or mortality were observed for 14 days. Further assays such as the oral glucose tolerance test, histopathological examination and antioxidant activity was also performed according to standard protocols | ||
| 520 | |a RESULTS: Findings exhibited that both single and repeated oral doses of PGLAE (40 mg/kg) produced significant reduction of blood glucose levels in normal and diabetic rats. All treated animals survived and no apparent adverse effects were observed during the duration of the acute toxicity study. Importantly, oral LD50 of PGLAE was greater than 2000 mg/kg BW. Furthermore, a remarkable influence on glucose tolerance was also noticed after PGLAE treatment. Moreover, PGLAE was able to improve histopathological structure of liver and possesses a potential antioxidant effect in vitro | ||
| 520 | |a CONCLUSION: In conclusion, this study reports the antidiabetic effect of PGLAE in rats supporting then its traditional use for the management of diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antihyperglycemic | |
| 650 | 4 | |a Pelargonium graveolens | |
| 650 | 4 | |a medicinal plant | |
| 650 | 4 | |a streptozotocin | |
| 650 | 4 | |a toxicity | |
| 700 | 1 | |a Amthaghri, Smail |e verfasserin |4 aut | |
| 700 | 1 | |a Akdad, Mourad |e verfasserin |4 aut | |
| 700 | 1 | |a El-Haidani, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Eddouks, Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological disorders drug targets |d 2006 |g (2022) vom: 16. Feb. |w (DE-627)NLM163039259 |x 2212-4063 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:16 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871529X22666220216102243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 16 |c 02 | ||